Aptamer Group plc, a developer of next-generation synthetic binders for the life sciences industry, has signed a new therapeutic development agreement with Invizius, a clinical-stage biotechnology company focused on second-generation complement system therapies for inflammatory, fibrotic, and autoimmune diseases. Under the terms of the agreement, Aptamer will develop Optimer binders targeted to critical factors of the complement system for an undisclosed sum. The targeted Optimers will help s...